RxDoctor Payments DataLook up a doctor →

Sujata Gutti, MD

Neurology · Pikeville, KYNPI 1831299346

Payments from drug & device makers

$85,778in general payments, 2019–2025

Across 905 payments — averaging $94.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$74K
  • Biogen$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Novartis$613
  • Pfizer$540
  • plus $6K from 48 others

What the payments were for

  • Speaking & faculty fees$71,19183%
  • Food & beverage$14,12916%
  • Education$4581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,778 in reported general payments places this provider in the 85th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$125,515
Medicare patients
384
Services billed
4,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant153$172,571
Kesimpta PenOfatumumab12$117,048
AustedoDeutetrabenazine21$107,028
XcopriCenobamate61$69,807
Nurtec OdtRimegepant Sulfate47$69,316
QuliptaAtogepant52$67,554
AptiomEslicarbazepine Acetate36$66,802
Emgality PenGalcanezumab-Gnlm64$50,219
GocovriAmantadine Hcl24$41,344
BotoxOnabotulinumtoxina18$24,355
GlatopaGlatiramer Acetate17$23,908
BriviactBrivaracetam13$20,241
Ajovy SyringeFremanezumab-Vfrm21$14,643
Oxcarbazepine165$11,045
Aimovig AutoinjectorErenumab-Aooe13$9,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$74,315$264,479223 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,081$107,02821 claims
SK Life Science, Inc.Xcopri$346$69,80761 claims
PfizerNurtec Odt$540$69,31647 claims
Sunovion Pharmaceuticals Inc.Aptiom$298$66,80236 claims
MDD US Operations, LLCGocovri$419$41,34424 claims
UCB, Inc.Briviact$1,409$20,24113 claims
Upsher-smith Laboratories LLCTopiramate$31$1,470274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 neurology providers in Kentucky.

Other neurology in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →